Logo image of GERN

GERON CORP (GERN) Stock Price, Quote, News and Overview

NASDAQ:GERN - Nasdaq - US3741631036 - Common Stock - Currency: USD

2.57  -0.06 (-2.28%)

After market: 2.57 0 (0%)

GERN Quote, Performance and Key Statistics

GERON CORP

NASDAQ:GERN (2/21/2025, 8:23:23 PM)

After market: 2.57 0 (0%)

2.57

-0.06 (-2.28%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High5.34
52 Week Low1.64
Market Cap1.55B
Shares604.50M
Float603.98M
Yearly Dividend0
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)02-26 2025-02-26/bmo
IPO07-31 1996-07-31


GERN short term performance overview.The bars show the price performance of GERN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

GERN long term performance overview.The bars show the price performance of GERN in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 50 100

The current stock price of GERN is 2.57 USD. In the past month the price decreased by -14.9%. In the past year, price increased by 31.12%.

GERON CORP / GERN Daily stock chart

GERN Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About GERN

Company Profile

GERN logo image Geron Corp. operates as a biotechnology company. The company is headquartered in Foster City, California and currently employs 141 full-time employees. The firm is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. The company is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. The company is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.

Company Info

GERON CORP

919 East Hillsdale Boulevard, Suite 250

Foster City CALIFORNIA 94404 US

CEO: John A. Scarlett

Employees: 141

Company Website: https://www.geron.com/

Investor Relations: https://ir.geron.com/

Phone: 16504737700

GERON CORP / GERN FAQ

What is the stock price of GERON CORP today?

The current stock price of GERN is 2.57 USD. The price decreased by -2.28% in the last trading session.


What is the ticker symbol for GERON CORP stock?

The exchange symbol of GERON CORP is GERN and it is listed on the Nasdaq exchange.


On which exchange is GERN stock listed?

GERN stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for GERON CORP stock?

15 analysts have analysed GERN and the average price target is 7.88 USD. This implies a price increase of 206.48% is expected in the next year compared to the current price of 2.57. Check the GERON CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is GERON CORP worth?

GERON CORP (GERN) has a market capitalization of 1.55B USD. This makes GERN a Small Cap stock.


How many employees does GERON CORP have?

GERON CORP (GERN) currently has 141 employees.


What are the support and resistance levels for GERON CORP (GERN) stock?

GERON CORP (GERN) has a support level at 2.55 and a resistance level at 2.78. Check the full technical report for a detailed analysis of GERN support and resistance levels.


Is GERON CORP (GERN) expected to grow?

The Revenue of GERON CORP (GERN) is expected to grow by 26300.3% in the next year. Check the estimates tab for more information on the GERN EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy GERON CORP (GERN) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does GERON CORP (GERN) stock pay dividends?

GERN does not pay a dividend.


When does GERON CORP (GERN) report earnings?

GERON CORP (GERN) will report earnings on 2025-02-26, before the market open.


What is the Price/Earnings (PE) ratio of GERON CORP (GERN)?

GERON CORP (GERN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.32).


What is the Short Interest ratio of GERON CORP (GERN) stock?

The outstanding short interest for GERON CORP (GERN) is 12.35% of its float. Check the ownership tab for more information on the GERN short interest.


GERN Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

GERN Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to GERN. GERN may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GERN Financial Highlights

Over the last trailing twelve months GERN reported a non-GAAP Earnings per Share(EPS) of -0.32. The EPS increased by 5.88% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -45.22%
ROE -68.83%
Debt/Equity 0.04
Chartmill High Growth Momentum
EPS Q2Q%50%
Sales Q2Q%17138.41%
EPS 1Y (TTM)5.88%
Revenue 1Y (TTM)9409.68%

GERN Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to GERN. The Buy consensus is the average rating of analysts ratings from 15 analysts.

For the next year, analysts expect an EPS growth of 14.69% and a revenue growth 26300.3% for GERN


Ownership
Inst Owners81.67%
Ins Owners0.09%
Short Float %12.35%
Short Ratio6.36
Analysts
Analysts85.33
Price Target7.88 (206.61%)
EPS Next Y14.69%
Revenue Next Year26300.3%